Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

RMReid W. MerrymanAAAsh A. AlizadehJVJenna Voutsinas

Discussion

Loading...

Member takes

Overview

Phase 2 trial reduces chemotherapy with dual therapy in advanced Hodgkin lymphoma, suggesting improved outcomes.

Key Points

  • The trial aims to personalize chemotherapy intensity in advanced Hodgkin lymphoma based on ctDNA evaluation.
  • Multi-center phase 2 trial involving response-adapted therapy based on MRD testing using PhasED-Seq.
  • Patients receive nivolumab, doxorubicin, vinblastine, and dacarbazine in 28-day cycles.
  • MRD testing is performed at baseline and after two cycles; therapy is adjusted based on results.
  • The primary endpoint is 1-year progression-free survival for patients with undetectable MRD after two cycles.
  • The primary efficacy benchmark is a 1-year progression-free survival rate of ≥94% for ctDNA-negative patients.
  • Approximately 80% of patients are expected to be ctDNA-negative at the third cycle's day one assessment.
  • If true 1-year PFS is 95% or 96%, there's a 77% and 89% chance of meeting the benchmark, respectively.

Cite This Study

Merryman et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d2d8https://doi.org/10.1182/blood-2025-5408
View Full Paper
Ask AI
Bookmark
Share